FILTER
FILTERED INTERVIEW RESULTS
Ricardo Cuetos
VP AMERICAS STANDARD PRODUCTS, INEOS STYROLUTION
INEOS Styrolution explains the current market dynamics of the America’s and how it’s various units are coping.
Paul Hennessey
SENIOR VICE PRESIDENT – OPERATIONS, QUALITY AND TECHNICAL SERVICES, ADVANTICE HEALTH
Advantice Health provides consumer health care products and is focused on building a number of brands.
Dr. Jeffrey Reingold
COO, CONTRACT PHARMACAL CORP
CPC, a full-service contract manufacturer in the US, comments on the current business environment.
Roel Schaapveld
CEO, INTERNA TECHNOLOGIES
InteRNA is a Dutch biotechnology company specializing in the development of RNA therapeutics for the treatment of cancer.
Anthony Capobianco
FOUNDER AND PRESIDENT, STEMSYNERGY THERAPEUTICS
StemSynergy Therapeutics (SSTI) is a biotechnology company focused on discovering drugs that target biomolecules and cellular processes fundamental to cancer.
Manni Kantipudi & Dr. Ramesh Subramanian
CHIEF EXECUTIVE OFFICER & CHIEF COMMERCIAL OFFICER, GVK BIO
GVK BIO is a global contract research and development organization (CRDO) providing drug discovery and development services to the biopharma industry.
Ed Ikeguchi
CEO, AICURE
AiCure is an AI and advanced data analytics company targeting the health industry.
Martin Sack
REGIONAL HEAD AMERICAS, LESCHACO
Leschaco is a freight forwarder expanding its’ services and network across the Americas.
James Sapirstein
PRESIDENT AND CEO, AZURRX BIOPHARMA
AzurRx BioPharma is a development stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions.
Dr. Trevor P. Castor
PRESIDENT & CEO, APHIOS
Aphios’ vision is to develop biotechnology products for improving health and treating chronic diseases in an environmentally sustainable manner.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
